Crixivan capsule is an inhibitor of human immunodeficiency protease. Crixivan belongs to group of antiviral drugs that stops HIV from multiplication in our body Crixivan is not required for HIV and Aids and it is prescription drug provided under the guidance of medical practioners.
Indications of Crixivan
Crixivan mainly used with combination of other antiretroviral to treat HIV infection.
The drug uses are based on two clinical trials specifically for 1-year duration which defined as
1. Decrease in the risk of AIDS-defining illness or death
2. A prolonged excretion of HIV RNA.
Mechanism of action
An enzyme HIV-1 protease is required for the proteolytic gap of the viral polyprotein precursors integrate to the individual functional proteins form in HIV-1 infectious. Indinavir add to the protease active site and inhibits the activity of the enzyme. This barrierprohibitscleavage of the viral polyproteins causing in the formation of immature non-infectious viral particles.
How the drug administrated and dosage
The recommended dosage for adult is Crixivan is 800mg administer as two 400mg capsules given orally every 8 hours in concomitant use with other antiretrovirals to treat HIV infections.
Crixivan 800mg plus Ritonavir 100mg to 200mg twice a day The patients taking Crixivan must be take intervals of 8 hours Crixivan should give without food with water 1 hour before or 2 hours after meal.
It can be also taken with other liquids such as skim milk,juice,coffee or tea or with a light meal The patients ensure adequate hydration its prescribed adults drinks at least 1.5 liters of liquids during 24 hours
Blood in urine, Just below ribs severe back pain
Abdominal pain, Chills, Loss of appetite, Dizziness, Fever, Headache, Unpleasant breath odor, Vomiting of blood
Confusion, Dehydration, Dry or itchy skin, Fruity mouth odor, Increased hunger, Increased urination, Pale skin, Troubled breathing with exertion, Unusual bleeding or bruising, Unusual tiredness or weakness, Vomiting, Weight loss
Warning and safety measures
Acute hemolytic anemia includes cases result in death. Hence stop the course of Crixivan capsules
The patient having hepatitis has been treated with Crixivan will leads to hepatic failure and death.
Nephrolithiasis events cumulative frequency increase with increasing exposure of Crixivan hence risk over time remains the same The pharmacological action and long-term consequence of these events are currently unknown. A causal relationship has not been established.